Al-Samkari H, et al. - Researchers created a clinical treatment pathway for inpatient and outpatient use that involved the use of antifibrinolytic agents to manage hemoptysis in cystic fibrosis (CF). They compared the rates of admission for bleeding before and after implementation of this pathway. They analyzed all adult CF patients who received systemic antifibrinolytic agents over a 54-month period in adherence with the treatment pathway. They obtained information regarding demographics, baseline CF-related characteristics, and bleeding and treatment parameters. Overall, 21 adult CF patients with 72 distinct episodes of hemoptysis treated with antifibrinolytic agents were analyzed. Hospital admissions were reduced as a result of the implementation of a pathway utilizing systemic antifibrinolytic therapy to treat hemoptysis in CF patients. Findings revealed no serious adverse events.